Skip to main navigation

Skip to content

Menu

Home
About
Baxdrostat (CIN-107)
Pipeline
Investors
Contact

INVESTORS >> News Releases

Year

News Release

June 1, 2022

CinCor Pharma Doses First Patient in Phase 2 FigHTN-CKD Trial Evaluating the Selective Aldosterone Synthase Inhibitor Baxdrostat (CIN-107) in Patients with Uncontrolled Hypertension and Chronic Kidney Disease

News Release

May 31, 2022

CinCor Pharma to Present at the Jefferies Healthcare Conference

News Release

May 17, 2022

CinCor Pharma to Present at Upcoming Investor Conferences

News Release

May 10, 2022

CinCor Reports First Quarter Financial Results and Provides Corporate Update

News Release

April 19, 2022

CinCor Pharma to Participate in Jefferies Biotech on the Bay Summit

News Release

March 22, 2022

CinCor Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update

News Release

March 17, 2022

CinCor Pharma to be Added to Russell 2000® and Russell 3000® Indexes

News Release

March 15, 2022

CinCor Pharma to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on March 22, 2022

News Release

March 3, 2022

CinCor Pharma to Present at the 32nd Annual Oppenheimer Healthcare Conference

News Release

January 13, 2022

CinCor Pharma Appoints June Lee to Its Board of Directors

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 12

Email Alerts
Contact Us
RSS Feeds

Home
About
Baxdrostat (CIN-107)
Pipeline
Investors
Contact

© 2022 CinCor. All rights reserved

Privacy
LinkedIn
Twitter